HSBC analyst Morten Herholdt raised the firm’s price target on Biogen (BIIB) to $150 from $143 and keeps a Reduce rating on the shares. The firm says the uncertain macro backdrop, rising geopolitical risk, and lower exposure to AI disruption risks could attract investors to healthcare and drive outperformance in the coming quarter.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Biogen Announces Upcoming Departure of Chief Legal Officer
- Biogen presents additional results from Phase 1b study of salanersen
- Stoke Therapeutics, Biogen publish data from zorevunersen studies in NEJM
- Biogen Deepens Its ALS Footprint With Long-Term Qalsody Safety Registry
- Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst